Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genetic Signals Reflect the Evolutionary Impact of Cholera

Published: Monday, July 08, 2013
Last Updated: Monday, July 08, 2013
Bookmark and Share
Study identifies regions of genome associated with cholera susceptibility in Bangladesh.

An international research team has used a novel approach to identify genetic factors that appear to influence susceptibility to cholera. The findings by investigators from Massachusetts General Hospital (MGH), the Broad Institute and the International Center for Diarrhœal Disease Research, Bangladesh (ICDDR,B) indicate the importance of pathways involved in regulating water loss in intestinal cells and of the innate immune system in the body's response to the bacteria that causes cholera, which affects from 3 to 5 million people each year and causes more than 100,000 deaths.

"We sought to understand cholera by studying the genetics of a population that has been affected by the disease for centuries – people in the Ganges River Delta of Bangladesh," says Regina LaRocque, MD, MPH, of the MGH Division of Infectious Diseases, a co-senior author of the report receiving online publication in Science Translational Medicine. "Our findings are just a first step, but they demonstrate how combining ancient history with the current impact of an infectious disease can be a powerful way of identifying human genes that are important to disease outcome."

Cholera is contracted by consuming water or food contaminated with the bacteria Vibrio cholerae, which releases a toxic protein upon reaching the small intestine. This toxin binds to the intestinal surface, causing severe diarrhea and potentially death from dehydration. Cholera or a cholera-like illness has been reported in the Ganges Delta for centuries, and most recent global outbreaks of the disease originated in that region. A potential fingerprint of cholera's genetic impact could be the relative rarity in the region of blood type O, which also confers an increased risk of severe cholera symptoms. The persistence of cholera in the Ganges Delta would be expected to exert an evolutionary force on the population, since individuals with gene variants that reduce their susceptibility to the disease would be more likely to survive and pass those variants along to their children.

To search for genomic regions that affect cholera susceptibility, the team employed a new two-step approach. The first step used a method called Composite of Multiple Signals (CMS) – developed by the Broad team led by co-senior author Pardis Sabeti, MD, DPhil – to scan the genomes of 126 individuals from the Ganges Delta for patterns that signal a long-term increase in the prevalence of particular DNA segments, indicating the effects of natural selection. That scan identified 305 regions under selective pressure, many of which are involved in two important biologic functions: regulation of the passage of water through intestinal cells via structures called potassium channels and a signaling pathway involved in both the innate immune system and the maintenance of the intestinal lining.

The second step directly tested the potential impact of these selected regions on cholera susceptibility by comparing the genomes of 105 cholera patients from the region with those of 167 individuals who did not contract the disease despite being exposed to it in their homes. That comparison found that the genomic region most strongly associated with cholera susceptibility in this population was one that the CMS scan had indicated as being under strong selection pressure. Genes in this region relate to an innate immune signaling pathway. LaRocque's team had previously shown this pathway to be activated by exposure to cholera toxin, and the current study identified the potential involvement of several additional genes in that pathway.

"An exciting feature of this project was the way it brought together the expertise in population genetics and natural selection of our collaborators at the Broad Institute with the leadership in addressing the health problems of the developing world of the ICDDR,B team led by Firdausi Qadri, with whom we have a longstanding collaboration," says LaRocque, an assistant professor of Medicine at Harvard Medical School. "Understanding the basic biology of a disease is fundamental to making clinically relevant advances in treatment. Our laboratory is now working on further studies of the innate immune response to cholera, and we believe this work will be highly relevant to developing improved vaccines."

Lead and co-corresponding author of the Science Translational Medicine report is Elinor Karlsson of the Broad Institute. In addition to Firdausi Qadri, PhD, of ICDDR,B, who is a co-senior author along with LaRocque and Sabeti, the paper's co-authors are Jason Harris, Ok Sarah Shin, Crystal Ellis, Stephen Calderwood and Edward Ryan, MGH Infectious Diseases; Christine Becker and Lynda Stuart, MGH Developmental Immunology; Shervin Tabrizi, Ilya Shylakhter, Nick Patterson, Colm O'Dushlaine and Stephen F. Schaffner, Broad Institute; Atiqur Rahman, Fahima Chowdhury and Alaullah Sheikh, ICDDR,B; and Sameer Gupta, Harvard Medical School. Support for the study includes National Institutes of Health grants TW007409, AI058935, AI079198 and NIH Innovator Award DP2-OD006514-01; grants from the Howard Hughes Medical Institute, the American Cancer Society and the Packard Foundation; and an MGH Claflin Distinguished Scholar Award.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine. In July 2012, MGH moved into the number one spot on the 2012-13 U.S. News & World Report list of "America's Best Hospitals."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Obesity Prevents Treatment of Pancreatic Cancer
Researchers discover mechanism, linked to obesity, that increases inflammation and conditions in pancreatic cancer by creating an ideal micro-environment.
Tuesday, July 12, 2016
First Gene that Causes Mitral Valve Prolapse Identified
An international research collaboration led by MGH investigators has identified the first gene in which mutations cause the common form of mitral valve prolapse, a heart valve disorder that affects almost 2.5 percent of the population.
Tuesday, August 11, 2015
Evo-Engineered CRISPR-Cas9s Hit More Gene-Editing Targets
Scientists have engineered a more effective CRISPR- Cas9 system paving the way for more advanced applications.
Wednesday, June 24, 2015
Powerful Gene-Editing Tool Appears to Cause Off-Target Mutations in Human Cells
Results indicate need to improve precision of CRISPR-Cas RNA-guided nucleases.
Wednesday, June 26, 2013
Mass. General, Duke Study Identifies Two Genes that Combine to Cause Rare Syndrome
Mutations in genes that regulate cellular metabolism found in families with ataxia, dementia and reproductive failure.
Monday, May 13, 2013
Circulating Tumor Cells can Reveal Genetic Signature of Dangerous Lung Cancers
MGH-developed device promises improvements in targeted therapy, treatment monitoring.
Friday, July 04, 2008
Gene Variation may Elevate Risk of Liver Tumor in Patients with Cirrhosis
A single alteration in the epidermal growth factor (EFG) gene may greatly increase the risk of developing hepatocellular carcinoma, researchers say.
Tuesday, January 08, 2008
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Sensor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!